Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526261 | 0.85 | PGR (0.38) | MMEAR | |
| SCHEMBL3874152 | 0.82 | PGR (0.40) | MMEAR | |
| SCHEMBL20195375 | 0.78 | ALDH1A1 (0.36) | PNMT | |
| SCHEMBL20176176 | 0.77 | ALDH1A1 (0.31) | PTPN2 | |
| SCHEMBL2065243 | 0.72 | — | — | |
| SCHEMBL4572759 | 0.72 | — | — | |
| SCHEMBL12496399 | 0.72 | — | — | |
| SCHEMBL24696502 | 0.70 | — | — | |
| SCHEMBL25468181 | 0.70 | KDM4E (0.46) | — | |
| SCHEMBL24961645 | 0.69 | PGR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| CN-1179753-C | Contraceptive compositions contaiing antiprogesting and progestinic | — | 2004-12-15 | — | — | CN | disclosed |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2004-09-23 | — | — | US | disclosed |
| EP-1173210-B1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | WYETH CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6759408-B2 | CYCLIC COMBINATION THERAPIES AND REGIMENS UTILIZING SUBSTITUTED INDOLINE DERIVATIVE COMPOUNDS WHICH ARE ANTAGONISTS OF THE PROGESTERONE RECEPTOR | WYETH | 2004-07-06 | — | — | US | disclosed |
| CN-1145618-C | Cyclocarbamate derivatives as progesterone receptor modulators | �Ʒ� | 2004-04-14 | — | — | CN | disclosed |
| US-6713478-B2 | SUCH AS 8-BROMO-6-(3-CHLORO-4-FLUOROPHENYL)-4,4-DIMETHYL-1,4-DIHYDRO-2H-3,1 -BENZOXAZIN-2-ONE; PROGESTERONE RECEPTOR ANTAGONISTS | WYETH | 2004-03-30 | — | — | US | disclosed |
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2003-11-20 | — | — | US | disclosed |
| US-6566358-B2 | 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma | WYETH | 2003-05-20 | — | — | US | disclosed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6498154-B1 | CONTRACEPTION; PROGESTATIONAL ACTIVE LEVONORGESTREL AND AN ANTIPROGESTIN COMPOUND | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| CN-1349415-A | Contraceptive compositions contaiing antiprogesting and progestinic | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1349517-A | Cyclocarbamate derivatives as progesterone receptor modulators | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C2, NR5A1, PGR | MME 4365/4885AR 21/4885GABRA1 137/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | MME 4336/4885AR 22/4885GABRA1 164/4885 |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | PGR, NR3C2, NR5A1 | MME 4435/4885AR 22/4885GABRA1 141/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | MME 4646/4885AR 21/4885GABRA1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.